33. Kapoor R, Saint S, Kapoor JR et al. Clinical problem-solving Background: The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate therapies for individual patients. We have now applied such testing to detect actionable mutations that may inform treatment recommendations in lung cancer.
introduction Recent insight into the molecular basis of lung cancer has led to changes in the treatment of this disease. The identification of driver mutations, such as those affecting the epidermal growth factor receptor (EGFR) [1] [2] [3] and anaplastic lymphoma kinase (ALK) genes [4] , has already been successfully translated into clinical practice with the implementation of treatment with approved targeted agents (erlotinib, gefitinib, and afatinib for EGFR, and crizotinib and alectinib for ALK). The subsequent discovery of ROS1 and RET rearrangements as potentially treatable targets suggested that several chromosomal translocations and corresponding gene fusions may serve as a driving force for nonsmall-cell lung cancer (NSCLC) [5] [6] [7] [8] . Genetic alterations that are targetable by therapeutic agents have now been identified in ∼50% of lung adenocarcinomas and include those affecting EGFR, ERBB2, KRAS, ALK, BRAF, PIK3CA, AKT1, ROS1, NRAS, and MAP2K1 [9] [10] [11] , and several clinical trials are ongoing in subgroups of patients harboring specific molecular changes such as activating mutations in BRAF, PIK3CA, or KRAS. Actionable genetic abnormalities have also been described in smoking-related squamous cell carcinoma (SCC) of the lung, including fibroblast growth factor receptor 1 gene amplification [12] and discoidin domain-containing receptor 2 (DDR2) gene mutation [13] .
The need to test for many mutations with a limited amount of tissue poses a problem for the 'one companion diagnosticone drug' paradigm of targeted cancer therapy. The clinical implementation of genomic profiling for NSCLC with highthroughput and multiplex genotyping tests is thus warranted in order to allow prioritization of appropriate therapies for individual patients. The amplicon-based next-generation sequencing (NGS) approach has been introduced to facilitate the performance of multiple genomic tests on the small amount of tissue available in a single formalin-fixed, paraffin-embedded (FFPE) tumor specimen obtained by transbronchial lung biopsy. To detect potentially actionable mutations that may influence treatment recommendations in lung cancer, we have now prospectively applied the Ion AmpliSeq Colon and Lung Cancer Panel and Ion AmpliSeq RNA Fusion Lung Cancer Research Panel (Life Technologies, Carlsbad, CA), which support target enrichment for NGS with the Ion Torrent platform and allow assessment in a single analysis of mutational hotspots in 22 genes related to lung and colon tumorigenesis as well as of 72 major variants of ALK, RET, ROS1, and NTRK1 fusion transcripts, respectively. On the basis of tumor molecular profile, we then determined the proportion of patients treated with genotypedirected targeted therapy and assessed their outcome.
patients and methods patients
Patients were recruited from individuals set to undergo either biopsy for the purpose of diagnosis or curative surgery for lung cancer, or from those with already histologically proven lung cancer, at Kinki University Hospital. Patients were eligible for genetic testing of their cancer if they had a histologically confirmed diagnosis of lung cancer, if both clinical information and an FFPE 'tissue block obtained before treatment were available, and if ' ≥10% of the tissue area in the guide hematoxylin-eosin slide was occupied by invasive cancer cells as evaluated by a pathologist. All specimens were fixed as for routine pathological diagnosis. No restrictions on tumor histology, disease stage, subsequent or previous treatment, performance status, or other factors were imposed. All patients provided written informed consent to the performance of genomic analysis, and the study was approved by the Institutional Review Board of Kinki University. Genetic alterations were defined as actionable if they were associated (or potentially associated) with susceptibility to an approved targeted therapy or if they could serve as a basis for direction of patients toward registered clinical trials (either nationally or at our institution) [14] . There were two primary end points for the study: (i) the percentage of patients with additional therapy options uncovered by de 
results

patient characteristics
Between July 2013 and March 2015, written informed consent was obtained from 138 patients at Kinki University Hospital who were set to undergo either biopsy for the purpose of diagnosis or curative surgery for lung cancer, or whose disease had already been histologically proven. Twenty-eight of these 138 patients were subsequently excluded from the study because they refused to undergo biopsy (n = 2), they were transferred to another hospital (n = 5), they had no proof of malignancy (n = 4), they were diagnosed with a primary malignant neoplasm other than lung cancer (n = 4), they had only a cytology specimen available (n = 4), they had no tissue remaining for further genetic analysis (n = 3), or their FFPE blocks contained insufficient tumor tissue (n = 6). Specimens from 110 patients with lung cancer were thus considered adequate for genomic testing (supplementary Figure S1 , available at Annals of Oncology online). The demographics of these 110 patients included in the study are shown in Table 1 . Thirty-seven (34%) patients were female, and 39 (35%) were never or light smokers, with the median age of all patients being 70 years (range, 39-87). Most (95%) patients had a good Eastern Cooperative Oncology Group performance status (0 or 1) at the time of testing. Seventy-eight (71%) patients had adenocarcinoma, and 60 (55%) had disease of stage IV. Seventy (64%) specimens were derived from tissue obtained at tumor biopsy, and 40 (36%) were from surgically resected tissue.
prevalence of genetic alterations in lung cancer
The 110 specimens were subjected to extraction of DNA and RNA, yielding median amounts of 754 ng (range, 6-8349 ng) and 401 ng (range, 18-1810 ng), respectively. There was no difference in sequencing quality between specimens obtained at biopsy and those collected during surgery. For DNA sequencing, 10 ng of DNA were subjected to library preparation for 105 of the 110 patients, and <10 ng of DNA were available for the Table 2 ). The most common genetic alterations were TP53 mutations in 42 (38%) patients, followed by EGFR mutations in 25 (23%), STK11 mutations in 12 (11%), KRAS mutations in 10 (9%), MET mutations in 7 (6%), SMAD4 mutations in 7 (6%), ERBB4 mutations in 4 (4%), FBXW7 mutations in 4 (4%), PIK3CA mutations in 4 (4%), and BRAF, AKT1, DDR2, and CTNNB1 mutations in 2 each (2%). Among the 25 EGFR mutation-positive cases detected by the NGS assay, 22 cases (88%) yielded concordant results with a commercially available mutation-specific PCR test (Scorpion ARMS), whereas 1 case yielded a discordant result and 2 cases were not assayed with the commercial test. For RNA sequencing, 10 ng of RNA were subjected to library preparation for 101 of the 110 patients, and <10 ng of RNA were available for the remaining 9 samples. Three of the 101 samples with sufficient RNA and 1 of the 9 with a potentially insufficient amount of RNA did not yield adequate libraries. Among all 110 specimens referred for analysis with the fusion transcript panel and direct sequencing, 106 (96%) were thus tested successfully. An ALK fusion was identified in one case (EML4-ALK), RET fusions in two cases (CCDC6-RET and KIF5B-RET in one each), and a ROS1 fusion in one case (SLC34A2-ROS1), whereas no NTRK1 fusion was detected ( Figure. 1, Table 2 ). All gene fusions were detected in patients with adenocarcinoma, with the frequencies of ALK, RET, and ROS1 rearrangements among such patients (n = 78) thus being 1.3%, 2.6%, and 1.3%, respectively. All four detected rearrangements were confirmed by FISH analysis (Figure 1 ), and they were mutually exclusive with other actionable genetic alterations.
identification of novel RET amplification and DDR2 mutations in lung cancer
The Ion AmpliSeq RNA Fusion Lung Cancer Research Panel was designed to detect 5 0 and 3 0 expression imbalance as an indicator of ALK, ROS1, RET, or NTRK1 translocations. Such allelic imbalance of RET without RET translocation was observed in an SCC tumor. FISH analysis with break-apart probes for RET thus did not detect a RET gene split (supplementary Figure S2A , available at Annals of Oncology online), whereas such analysis with RET and CEN10p probes revealed RET amplification (supplementary Figure S2B , available at Annals of Oncology online) in the tumor cells of this patient. The Ion AmpliSeq Colon and Lung Cancer Panel and NGS analysis also revealed two novel somatic mutations (W251R and L604P) in DDR2, resulting in an overall frequency of 2% for DDR2 mutations in the 110 tumor specimens (supplementary Figure S2C and D, available at Annals of Oncology online). To examine the oncogenic potential of these novel mutations of DDR2, we infected HEK293 cells with retroviruses encoding WT or W251R or L604P mutant forms of human DDR2 (supplementary Figure S3A and B, available at Annals of Oncology online). However, expression of WT or either mutant form of DDR2 had no effect on cell proliferation in the absence or presence of dasatinib (supplementary Figure S3C and D, available at Annals of Oncology online), indicating that both mutations lack oncogenic potential. The patients harboring RET amplification or DDR2 mutations identified in the present study did not receive corresponding targeted therapy such as that with vandetanib or dasatinib, respectively.
proportion and survival of patients treated with genotype-directed therapy Actionable genetic alterations were identified in 44 (40%) of the 110 study patients and included mutations in AKT1, BRAF, EGFR, KRAS, NRAS, PIK3CA, and STK11 as well as ALK, RET, and ROS1 fusions ( Table 2) . Thirty-nine (50%) of the 78 patients with adenocarcinoma harbored an actionable alteration, whereas only 3 (14%) of the 22 patients with SCC and none of those with small-cell lung cancer did so ( Table 2 ). The decision to recommend a targeted therapy to a patient with a tumor harboring an actionable genetic change was left to the treating physician. Among the 37 patients with advanced or recurrent lung cancer harboring actionable mutations, 23 individuals (62%) received targeted therapy, including that with either clinically approved (n = 16) or experimental (n = 7) agents. Eighteen (95%) of the 19 such patients with EGFR mutations and all three of those harboring a gene fusion thus received targeted therapy, whereas only 2 (25%) of the 8 with KRAS mutations Table S1 , available at Annals of Oncology online). The median follow-up for patients with advanced or recurrent lung cancer (n = 85) was 12.3 months, and the median OS for these patients was 23.5 months. The relation of targeted therapy implementation to OS in such patients with actionable genetic alterations is shown in Figure 2 . Patients with an actionable alteration who were treated with a targeted agent had a significantly longer OS compared with those without an actionable genetic change [median OS, not reached versus 18.1 months; hazard ratio (HR) 0.44, with a 95% CI 0.20-0.97; P = 0.041] or with those with an actionable change who did not receive targeted therapy (median OS, not reached versus 6.1 months; HR 0.14, with a 95% CI 0.04-0.51; P = 0.0027).
discussion
The development of targeted therapies for lung cancer based on the presence of therapy-specific biomarkers has highlighted the need for molecular diagnostic tests capable of the analysis of multiple genes in a single tumor sample in order to allow determination of the optimal therapy. However, the small size of tumor specimens obtained by transbronchial lung biopsy has presented a challenge to the achievement of adequate biomarker coverage for therapy decision making based on the sequential performance of many single-gene diagnostic tests. We have now applied NGS technology to allow the simultaneous, multiplex analysis of mutations in 22 known lung cancer susceptibility genes with tumor DNA as well as of fusion transcripts derived from 37 ALK, 9 RET, 15 ROS1, and 11 NTRK1 rearrangements with tumor RNA extracted from lung tumor specimens. Most of the collected specimens (64%) were obtained by transbronchial biopsy and were small in size; however, the DNA and RNA samples extracted from the FFPE tumor tissue were successfully genotyped with amplification efficiencies of >90% (95% and 96% for DNA and RNA sequencing, respectively), values higher than those described for other lung cancer studies [15, 16] , thus satisfying the requirements for multiplex analysis of somatic gene alterations with a single small tumor specimen.
Actionable genetic alterations potentially treatable with therapeutic agents were identified in 40% of all lung tumors, and in 50% of lung adenocarcinomas, consistent with previous findings [9] [10] [11] . The frequency of EGFR mutations in our study (23%) is lower than that previously determined for Japanese patients with NSCLC [17] . Given that EGFR mutation tests have been commercially available with insurance coverage since 2007 in Japan, many EGFR mutation-positive patients were not eligible for the present study as a result of the detection of their mutations prior to the application of NGS analysis. Most patients with advanced or recurrent NSCLC positive for EGFR mutations identified in the present study were treated with EGFR tyrosine kinase inhibitors. On the other hand, although we included KRAS and PIK3CA mutations as potentially actionable alterations, the proportion of patients with tumors positive for such mutations who received targeted therapy was low. Few investigational drugs that target mutant KRAS or an overactive KRAS signaling pathway are currently available in Japan, although several potential inhibitors that target downstream signaling molecules such as MEK have been developed for therapeutic testing outside of Japan [18, 19] .
Limitations of the present study include its observational and nonrandomized design for comparison of OS among patients with tumors with an identified oncogenic driver according to whether or not they received a targeted therapy. Indeed, this analysis essentially compared outcomes between patients with or without EGFR, ALK, ROS1, or RET alterations. Moreover, it remains unclear whether targeted treatment of patients positive for actionable changes other than EGFR mutations or ALK rearrangement showed an efficacy similar to that for treatment of patients positive for EGFR or ALK alterations with corresponding tyrosine kinase inhibitors. Although no definitive conclusions can be drawn, we found that OS of patients harboring an oncogenic driver who received treatment with a targeted therapy was significantly longer than that of those who did not. The patients harboring an oncogenic driver who did not receive targeted therapy (n = 14) included one with an EGFR mutation-positive tumor who could have been treated with an approved EGFR tyrosine kinase inhibitor as well as two patients with tumors positive for the V600E mutation of BRAF who were potential candidates for trials with BRAF inhibitors [20] . An early determination of eligibility for treatment with an appropriate targeted agent should thus be considered for such patients. Although the identification of known actionable targets for therapy selection is a high priority for studies of this type, the amplicon sequencing technique also allows detection of novel and potentially actionable mutations in target genes. In the present study, two novel DDR2 mutations (L604P, W251R) were identified, with the L604P mutation being localized to the kinase domain of DDR2. The kinase domain mutations I638F and G774V, which are located near L604P, have been associated with sensitivity to dasatinib in preclinical studies [13, 21] , suggesting that this novel kinase domain mutation might also confer sensitivity to dasatinib. However, we found that forced expression of either the L604P or W251R mutant of DDR2 did not affect the proliferation of HEK293 cells in the absence or presence of dasatinib, indicating that both mutations lack oncogenic potential.
In conclusion, we have demonstrated the successful application of the amplicon-based NGS approach to the performance of multiple genomic tests with a single, small FFPE tumor specimen obtained by transbronchial lung biopsy. Such multiplex genomic testing will assist physicians in matching patients found to harbor actionable mutations with available targeted treatments or clinical trials of new targeted agents.
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